WeedLife News Network

A temporary scheme enabling patients in Ireland easier access to their prescribed medical cannabis treatments has been made permanent.

In Ireland, specialist medical consultants can prescribe medical cannabis for patients with certain conditions assuming an appropriate application is submitted to the Department of Health and accepted. The country’s Medical Cannabis Access Programme kicked off in 2019 on a pilot basis for five years.

Currently, only three medications can be used – High CBD Oil Drops from Aurora, CannEpil from MGC Pharmaceuticals and THC10:CBD10 from Tilray. But it hasn’t been a case of popping down to the local pharmacy to pick up the medicines. The majority of patients of licenced clinicians obtain their prescribed products from Transvaal Pharmacy in the Hague in the Netherlands.

Prior to the COVID-19 pandemic, these patients or family members had to travel to the Netherlands to collect their medical cannabis prescription due to a ban in the Netherlands on commercial exports of cannabis oils. This created a great deal of stress for patients and their families, along with the significant added financial strain associated with making the trips.

A temporary delivery service from the Netherlands was established in April 2020 for the filling of individual prescriptions due to COVID-19 travel restrictions. It’s obviously worked out pretty well, and yesterday Minister for Health Stephen Donnelly announced this would be ongoing.

The Bureau of Cannabis Control‘s Cannabis Advisory Committee approved recommendations that would relax several regulations for the California cannabis industry, aimed at helping struggling cannabis businesses. The recommendations were included in the state panel’s annual report.

While arguably the largest state market for cannabis in the United States, California legal cannabis businesses struggle with competition from illegal cannabis sellers, among many other obstacles to expanded profitability. Though classified as essential services by the state, the businesses also have been affected by the COVID-19 pandemic and new public health requirements for retail and manufacturing industries.

“The state has faced unprecedented circumstances in 2020: the global COVID-19 pandemic and resulting recession, a record-breaking wildfire season, and the nationwide fight for racial justice and equality,” the seventeen-member panel reported. “With the additional pressures the cannabis industry faces during this challenging time in mind, the Advisory Committee sought to recommend policies that promote public health, set the stage for the proposed consolidation of the licensing authorities, and lead to economic recovery.”

Recommendations made by the panel included lifting the $5,000 limit on the cannabis products can be carried by delivery vans, which would allow retail businesses to offer a greater variety of products. The panel also recommended that cannabis lounges eventually be allowed to serve food and beverages.

The committee has not yet posted it’s final report, but a draft is available here.

Two weeks ago, I reported on the landmark ruling by the Court of Justice of the European Union (the CJEU) that cannabidiol (CBD) derived from the entire hemp plant is not a narcotic under the U.N. Single Convention on Narcotic Drugs of 1961 (the Single Convention); and thus, should be freely traded between European Union (EU) member states.

The same day that piece was published, the European Commission accepted the CJEU ruling and retracted its preliminary position on treating hemp-derived CBD and other extracts derived from the flowering tops of the Cannabis sativa L. plant as narcotics. This means that CBD ingestible products won’t be banned from the EU market and that European regulators have resumed the review of those existing CBD Novel Food Authorization applications.

Then, on December 2, 2020, the United Nations Commission for Narcotic Drugs (the CND) brought to a vote six recommendations made by World Health Organization (WHO) in 2019.

The Single Convention, an international treaty in which member countries pledge to ban the production and trade of certain drugs, including cannabis, except for medical and research purposes, categorizes drugs based on their possible harm versus medical utility. The Single Convention has four schedules: Schedules I and II are the main schedules, whereas Schedules III and IV are complementary schedules. Schedule IV is a stricter subset of Schedule I and includes substances considered to be the most harmful and with virtually no therapeutic value — this is in essence comparable to Schedule I of the U.S. Controlled Substance Act (the CSA).

Of the six WHO recommendations, only the proposal to remove cannabis and cannabis resin for medicinal purposes from Schedule IV of the Single Convention was approved by a close vote, passing 27 to 25, with the United States (the U.S.) and notable European nations in favor.

Mexico’s President Andres Manuel Lopez Obrador on Tuesday blamed small draft errors for a delay in approving a new law that would legalize cannabis and effectively create one of the world’s largest weed markets.

The bill was due to be approved by Dec. 15, but it has been delayed to next year, with the Supreme Court setting a new deadline of April 30 for the law to be passed, according to local media.

Lopez Obrador said legislators requested a delay as time had run out before the current session in Congress ended this month, meaning there was not enough time to review the bill.

“The period was practically over but they are matters of form and not substance,” Lopez Obrador said in his morning daily press conference, adding that the issues will be “resolved” in the next session due to start in February.

The bill, which would mark a major shift in a country bedeviled for years by violence between feuding drug cartels, easily passed the Senate in a vote last month, and would create a huge new legal market for marijuana.

Lawmakers haven’t given much consideration to how weed will be treated in places like casinos, mostly because everyone involved seems to be under the impression that it will be treated the same as booze and tobacco. 

New Jersey just legalized recreational marijuana in the November election, but don’t bet on Atlantic City’s casinos amending their policies to accommodate people who use the herb. That’s probably not going to happen, according to a report from the Press Of Atlantic City.

Although people have been secretly using marijuana in the hotels for years, people close to these operations say that’s only because management has turned a blind eye. However, now that marijuana is legal, the protocol might get a little more militant with respect to the “no marijuana” restrictions.

“I don’t think there’s going to be any real major change,” Dan Heneghan, an industry consultant and retired spokesperson for the state Casino Control Commission, told the news source. “The blind eye that (casinos) turn to that will just be opened.”

So far, the Casino Association of New Jersey has not come out and taken a definitive stance against marijuana use. But that is likely because marijuana regulations are still being hashed out in the state legislature. The truth is, New Jersey lawmakers haven’t really given much consideration to how marijuana will be treated in places like casinos, mostly because everyone involved seems to be under the impression that it will be treated the same as alcohol and tobacco. 

South Carolina lawmakers are slated to consider multiple bills next year that could legalize marijuana for either recreational or medicinal use.

Though some Democrats are pushing for complete decriminalization of the plant, there is a bipartisan effort to push legalization of medical marijuana in the state.

Medical marijuana bills prefiled this month in both the House and the Senate tout sponsors from both parties. If either bill — both named the “South Carolina Compassionate Care Act” — were to pass, South Carolina would join 36 other states in allowing the use of marijuana for medical purposes.

But bipartisan support hasn’t been enough to push through marijuana legislation in the past. Last session, two bipartisan bills, one in each the House and the Senate, didn’t make it out of their respective committees.

In the Senate last year, the bill became bogged down by amendments, including one that would only allow cannabis derivatives such as oils and creams. Neither bill resurfaced during 2020, when the session was cut short by COVID-19.

Right now, 36 states have legalized medical cannabis in some form. Advocates hope the Palmetto State is next.

Senator Tom Davis (R-Beaufort) prefiled S.150 the South Carolina Compassionate Care Act this week. Sen. Davis said he has been pushing for legalization of medical cannabis since 2014 and believes next year it has a chance to pass.

“I have a majority of state Senators who will vote for this and I have a majority of House members who will vote for this bill,” Davis said.

He called his bill the most conservative medical cannabis bill in the country. “We limit the qualifying conditions to medical conditions for which there is empirical evidence that medical cannabis can be a medicinal benefit.”

That list includes: cancer, multiple sclerosis, a neurological disease or disorder (including epilepsy), sickle cell anemia, glaucoma, PTSD, autism, Crohn’s disease, ulcerative colitis, cachexia, a condition causing a person to be home-bound that includes severe or persistent nausea, terminal illness with less than one-year life expectancy, a chronic medical condition causing severe and persistent muscle spasms, or a chronic medical condition for which an opioid is or could be prescribed based on standards of care.

Is it the seed of prosperity for Costa Rica? Despite the reluctance of the country’s president, the legalization of cannabis and its large-scale production has made its way through the national parliament thanks to the determination of an independent deputy who is an agronomist. Covered by the National Institute of Innovation in Agricultural Technology, Zoila María Volio wants to take advantage of the great economic potential of medicinal cannabis.

“The project was born as an initiative to make it work and to be able to generate a different crop for many agricultural cooperatives,” explains the deputy. The bill that Zoila María Volio promoted has the support of the majority of the chamber and only needs to be voted on in a plenary session. However, it clashes with the reluctance of the country’s president, Carlos Alvarado, who sees the production of hemp for export well but does not see so well the legalization of medical marijuana.

Different opinions
A diametrically opposite position maintains the businessman Rodrigo Martín. Suffering from cancer, two years ago he was diagnosed, and doctors told him that he would only live six months:

“I have one year, I think one year and three months, of not taking a single test, not a single exam. I decided to live. I live every day happy, I have quality of life, I enjoy my life, I have friends, a normal life, totally normal. And I owe it all, without a doubt, to God and cannabis”, he says.

Increasing demand
The current global demand for medical cannabis is worth almost six billion dollars annually, although this amount is expected to multiply in the coming years to meet the growing needs of the pharmaceutical industry in countries such as Germany. Manna for a Costa Rican agricultural sector that, like the entire region, has been the victim this year of the COVID-19 Pandemic, the economic crisis, and the hurricanes.

This week the U.N. Commission on Narcotic Drugs voted to remove cannabis and cannabis resin from a category of the world’s most dangerous drugs. This decision could potentially jumpstart the global medical marijuana industry. Many cannabis companies have eyed global expansion, but the markets have proven to be challenging as laws have remained strict.

The Vienna-based U.N. agency said in a statement that it had voted 27-25, with one abstention, to follow the World Health Organization’s recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Convention on Narcotic Drugs, where it was listed with heroin and several other opioids. The drugs that are on Schedule IV are a subset of those on Schedule I of the convention, which already requires the highest levels of international control. The agency voted to leave cannabis and cannabis resin on the list of Schedule I drugs, which also includes cocaine, Fentanyl, morphine, Methadone, opium and oxycodone, the opiate painkiller sold as OxyContin.

Wednesday’s vote does not clear U.N. member nations to legalize marijuana under the international drug control system. Canada and Uruguay have legalized the sale and use of cannabis for recreational purposes, but many countries around the world have decriminalized marijuana possession. The schedules weigh a drug’s medical utility versus the possible harm that it might cause.

European court of justice makes the call

Last week, the European Court of Justice (ECJ) determined that CBD, although technically a narcotic under the 1961 UN convention, should not be considered a narcotic given its lack of a psychoactive effect. The judgment came as part of a case between the French government and Kanavape that sought to limit the company’s ability to market CBD products produced (legally) in another state. Under this ruling, the ECJ (the highest court in the EU) has now allowed for cross-marketing of CBD products produced by leaves and flowers (in addition to seeds and stalks) among EU member nations and opens up the ability for companies to begin registering their products as Novel Foods (eventually allowing for marketing as a CBD food substance).

“The Court notes, next, that, to define the terms ‘drug’ or ‘narcotic drug’, EU law3 makes reference inter alia to two United Nations conventions: the Convention on Psychotropic Substances4 and the Single Convention on Narcotic Drugs.5 CBD, however, is not mentioned in the former and, while it is true that a literal interpretation of the latter might lead to its being classified as a drug, in so far as it is a cannabis extract, such an interpretation would be contrary to the general spirit of that convention and to its objective of protecting ‘the health and welfare of mankind’. The Court notes that, according to the current state of scientific knowledge, which it is necessary to take into account, unlike tetrahydrocannabinol (commonly called THC), another hemp cannabinoid, the CBD at issue does not appear to have any psychotropic effect or any harmful effect on human health.”

As marijuana legalization continues to sweep the county—and with Congress potentially moving to finally decriminalize pot on the federal level—a new poll shows that a huge majority of Americans support expunging the criminal records of those who have previously been busted.

The findings, which come via the pollster YouGov.com, found that 70 percent of respondents said yes when asked if they support or oppose “expunging marijuana-related convictions for non-violent offenders.” A mere 17 percent said they oppose the idea. 

Digging into the crosstabs, the poll found a partisan split—though not as wide as it likely was in previous eras. 81 percent of Democrats said they either strongly or somewhat support the idea, while a majority of Republicans—57 percent—said the same. 

The mounting evidence of bipartisan support for relaxed pot policies is reflected not only in surveys like this, but in results at the ballot box and actions on Capitol Hill. 

Last month saw voters in four states move to legalize recreational pot use for adults; two of those, South Dakota and Montana, were carried easily by President Donald Trump. Arizona and New Jersey were the other two states where voters approved legalization measures, while South Dakota voters additionally passed a similar measure legalizing medical marijuana. 

2020 was a historic year for marijuana legalization as four states — Arizona, Montana, New Jersey and South Dakota — legalized recreational marijuana for adults, and Mississippi legalized medical marijuana.

2021 could be another big year for the cannabis industry; MjBizDaily is predicting that these five states will probably legalize recreational marijuana for adults:
– Connecticut
– Maryland
– New Mexico
– New York
– Pennsylvania

“New York, Connecticut, Maryland, New Mexico are ripe for 2021” marijuana legalization via their legislatures, said Steve Hawkins from the MPP. “We’re at 15 (states that have legalized adult use) now, and it’s not outside the realm of possibility that we can be at 25 states” in the near future.”

In recent years, Maine, Massachusetts, and Vermont legalized recreational cannabis industries. These are adding fuel to the Northeast fire. The governors in New York and Pennsylvania have openly supported legalizing marijuana for adults for some time.

U.K. operation estimated to have a street value of $1.7 million.

Dismantling a sophisticated cannabis grow-op boasting 1,000 plants having an estimated street value of £1 million (about $1.7 million) made for quite a mess — and a big show — for neighbours in Clacton, U.K. last week.

Essex Police busted the illegal growing operation in a disused three-storey building after receiving reports of suspicious activity, according to a Facebook post from police. Work to dismantle the equipment and remove the approximately 1,000 plants started shortly after the raid and reportedly took much of the weekend to complete.

“Cannabis factories are linked to criminals who exploit vulnerable people for their own financial gain. These might be people who are exploited or forced to work for them to manage these cultivations, or to sell the drugs,” the statement notes.

“Organized crime groups involved in drug trafficking are typically also involved in a range of criminal activity, and the profits from illegal drugs are used to fund other forms of criminal operations, including buying illegal firearms and financing terrorism,” according to the National Crime Agency.

New Jersey officials are moving cannabis legalization forward.

New Jersey lawmakers and Democratic Gov. Phil Murphy announced last week that they had agreed on a plan to legalize recreational cannabis in the state. The deal comes following last month’s approval of a ballot measure that asked New Jersey voters to weigh in on the concept of legalizing marijuana but lacked details on establishing a regulated cannabis industry.

“There is a deal,” said Sen. Nicholas Scutari, the sponsor of the marijuana legalization bill, on Friday. “It’s been a long road and I’ll be happy when it’s done.”

State Leaders Hail Agreement
In a joint statement, Murphy, and fellow Democrats Scutari, Senate President Stephen Sweeney, Assembly Speaker Craig Coughlin, and Assembly Majority Conference Chair Annette Quijano said on Friday that the plan includes strong social equity provisions.

“We’re proud to announce today that we’ve reached an agreement on legislation providing the framework for legalization, which is a critical step in reducing racial disparities and social inequities that have long plagued our criminal justice system,” they said. “This legislation will accomplish our shared goals of delivering restorative justice and ensuring that the communities most impacted by the War on Drugs see the economic benefits of the adult-use cannabis market. While there is still much work ahead, we are one step closer to building a new, promising industry for our state.”

In September, the House postponed a vote on the MORE Act (H.R.3884), which would de-schedule cannabis. Now that this legislation has passed the House and moves onto the Senate, safety leaders must again warn lawmakers to exercise caution. While the MORE Act includes some provisions that would not cause workplace safety concern, such as the removal of punitive actions for drug violations, any de-scheduling of cannabis must be done with care. Steps toward legalization need to include an evaluation of the impact that legalized cannabis use will have on transportation and workplace safety. We have an obligation to protect workers and all who use our roadways, and cannabis use can create serious risks in both environments.

Data should always drive policy decisions. Cannabis is an impairing substance whose use has been on the rise, and a substance without clear and scientifically defined levels of impairment. Unfortunately, no cannabis test currently exists that correlates well with impairment level such as breath alcohol or blood alcohol. At this time we know little about cannabis impairment, the side effects or long-term health implications, as well as the implications for workplace safety. These questions can only be answered through rigorous research.

We know that cannabis has the ability to impair, and on-the-job impairment can have serious consequences, particularly for workers in safety-sensitive positions and all those around them. It is difficult to ascertain if a worker may be impaired, when they last used cannabis and whether they pose a risk to co-workers, customers or the general public. This is akin to the potential for “driving under the influence” for those operating commercial aircraft, trucks, trains, buses, cranes and forklifts. One troubling trend during the pandemic has been an increase in impaired driving, including from cannabis. Potential mishaps can also result from impairment of a worker on the floor of a chemical plant, at a construction site, warehouse or other operation with inherent risk.

Even among states that have legalized marijuana for adult recreational use, there is a worrisome lack of consensus on what occupations are considered to be “safety-sensitive” positions and when employers may conduct drug testing or institute a zero-tolerance drug policy for those positions. To meet their legal and ethical responsibilities, employers should be allowed and encouraged to maintain a substance-free workplace, regardless of the legal status of cannabis.

We urge that any steps taken towards legalization likewise explore the impact on transportation and workplace safety and ensure there is an evidence-based standard for detecting cannabis-impairment in driving and other safety sensitive operations. When it comes to impairment, we owe it to our employees and our communities to address the public safety side of cannabis first and foremost.

After an initial burst of celebration over last week’s House approval of the MORE Act, landmark legislation that would decriminalize marijuana at the federal level, the hard realization that getting the bill past the finish line and signed into law is an unlikely proposition is beginning to set in. Even some cannabis activists aren’t sure the bill is the right path to legalization, and getting the measure a fair hearing in the Senate while Mitch McConnell is at the reins isn’t at all likely.

Federal cannabis legalization is a longshot as long as Mitch McConnell is Senate Majority Leader. ... [+]

 GETTY IMAGES

With that reality in mind, a new group aimed at establishing a legal framework for cannabis interstate commerce was formed in September. Dubbed the Alliance for Sensible Markets, the group of activists and industry representatives has two primary goals. First, the group is working to bring two or more states with legal marijuana together to join in an interstate compact outlining the parameters for legal cannabis commerce between them. Secondly, a path to federal approval of the plan would have to be determined and executed. Paired with a federal policy that would permit state-legal cannabis businesses to operate without interference, interstate cannabis commerce could be a more politically viable path to many of the goals of full legalization.

The Flaws Of A Fragmented Market

Adam Smith, the founder and president of the alliance, said in a telephone interview that the current system of regulated cannabis trade, with each state that has legalized pot operating its own siloed market of production, manufacturing, distribution, and sales, is unsustainable. And in the real world, it’s also a system that is unworkable.

The U.S. House of Representatives voted in favor on this first-of-its-kind federal cannabis decriminalization bill. It was a partisan vote despite marijuana being a bipartisan issue. Democrats voted 213 YES and 6 NO, while Republicans voted 5 YES 156 NO.

Just after an election that saw four states legalize marijuana and two states legalize medical marijuana, it’s become clear that most Americans have a progressive view on marijuana. In fact, Pew Research reports that 67% of Americans support marijuana legalization.

As Steven Hawkins, executive director at the Marijuana Policy Project purports, “The prohibition and criminalization of marijuana has led to decades of injustice and devastating consequences, and it’s clear that a strong majority of Americans do not support the status quo.”

And the issue is bipartisan, with two of the legalizing states being Montana and South Dakota. But it’ll take a progressive Senate to pass such a progressive policy. And that’s where the MORE Act may run into trouble.

What is the MORE Act?

The MORE Act is the Marijuana Opportunity, Reinvestment and Expungement Act, a historic bill that was approved by the House Judiciary Committee for a floor vote by the U.S. House of Representatives on Wednesday, Dec 2, 2020.